goetzpartners securities Limited 08-Nov-2018 / 10:45 GMT/BST Free to access research and investor meetings in a post-MiFID2 world. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail […]
Category: Press Releases
08. November 2018
Epigenomics (ECX-DE): Q3 -Milestone completion triggers more commercial momentum
Read more
07. November 2018
Epigenomics AG: Epigenomics AG Announces 2018 Third Quarter and Nine Months Financial Results
DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement 07.11.2018 / 08:38 The issuer is solely responsible for the content of this announcement. Press release Epigenomics AG Announces 2018 Third Quarter and Nine Months Financial Results Berlin (Germany) and San Diego, CA (U.S.A.), November 7, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: […]
31. October 2018
Epigenomics AG Announces Veterans Administration’s Adherence Study using Epi proColon(R) Colorectal Cancer Screening Blood Test
DGAP-News: Epigenomics AG / Key word(s): Study 31.10.2018 / 13:29 The issuer is solely responsible for the content of this announcement. Press release Epigenomics AG Announces Veterans Administration’s Adherence Study using Epi proColon(R) Colorectal Cancer Screening Blood Test Berlin (Germany) and San Diego, CA (U.S.A.), October 31, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) […]
29. October 2018
Epigenomics AG obtains CE Mark for Liquid Biopsy Test for Liver Cancer Detection
DGAP-News: Epigenomics AG / Key word(s): Miscellaneous 29.10.2018 / 07:00 The issuer is solely responsible for the content of this announcement. Press release Epigenomics AG obtains CE Mark for Liquid Biopsy Test for Liver Cancer Detection – CE Mark for liver cancer blood test enables commercialization in Europe – Prospective U.S. trial for FDA submission […]
22. October 2018
Epigenomics AG: Centers for Medicare & Medicaid Services publish final rate of $192 for Epigenomics’ colorectal cancer screening blood test Epi proColon(R)
DGAP-News: Epigenomics AG / Key word(s): Miscellaneous 22.10.2018 / 07:33 The issuer is solely responsible for the content of this announcement. Press release Centers for Medicare & Medicaid Services publish final rate of $192 for Epigenomics’ colorectal cancer screening blood test Epi proColon(R) Berlin (Germany) and San Diego, CA (U.S.A.), October 22, 2018 – Epigenomics […]
10. October 2018
Epigenomics (ECX-DE): Strong tailwinds expected from Epi proLiver
goetzpartners securities Limited 10-Oct-2018 / 11:11 GMT/BST Free to access research and investor meetings in a post-MiFID2 world. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail […]